ddhNTP P2 Receptor Agonists for Host Defense Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanistic understanding of Viperin's broad-spectrum host defense mechanisms is incomplete, and the role of ddhCTP in activating nucleotide receptors for host protection and modulation of physiology remains unclear.
Innovation Solution
Development of synthetic and semisynthetic methods to produce non-natural ddhCTP and ddhATP derivatives that robustly activate P2 receptors, modulate physiology, and are used for immunomodulatory therapeutics, nucleotidase inhibitors, and host-acting anti-infectives through rational design and bioproduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Viperin catalyzes conversion of CTP to ddhCTP for host defense, then antimicrobial activity is achieved, but the mechanistic understanding of how ddhCTP activates nucleotide receptors remains incomplete
Solution Approach 1:
The patent performs preliminary actions by synthesizing and characterizing ddhCTP derivatives before testing their biological activity. The synthetic methods and structure-activity relationship studies are conducted in advance to establish the mechanistic basis for receptor activation, enabling subsequent therapeutic applications.
Solution Approach 2:
The patent introduces ddhCTP derivatives as intermediary molecules that mediate between Viperin enzyme activity and P2 receptor activation. These derivatives serve as signaling intermediaries that bridge the gap between viral sensing and host immune response, elucidating the previously unknown mechanism.
2Reliability
If synthetic methods are developed to produce ddhCTP derivatives, then robust P2 receptor activation is achieved, but the complexity of synthetic and semisynthetic production increases
Solution Approach 1:
The patent segments the synthesis into modular stages: (1) synthesis of ddh nucleoside building blocks, (2) phosphorylation to nucleotides, and (3) derivation to produce various ddhCTP analogs. This segmentation allows independent optimization of each step and simplifies the overall complex synthesis process.
Solution Approach 2:
The patent develops universal synthetic routes that can produce multiple ddhCTP derivatives from common intermediates. The semisynthetic approaches use enzymatic reactions that are substrate-promiscuous, allowing one enzyme system to produce multiple therapeutic analogs, reducing overall process complexity.
3Reliability
If ddhCTP derivatives are designed for enhanced P2 receptor activation, then immunomodulatory therapeutic potential is improved, but the difficulty of detecting and measuring their physiological effects increases
Solution Approach 1:
The patent implements feedback mechanisms by using P2 receptor-luciferase reporter assays to directly measure derivative activity. The structure-activity relationship data provides feedback loops where biological assay results guide further structural optimization, enabling iterative improvement of therapeutic candidates.
Solution Approach 2:
The patent employs luminescent reporters that produce optical signals (color changes) to detect P2 receptor activation. The luciferase-based assays convert biochemical activity into measurable light signals, simplifying detection and quantification of physiological effects.
4Adaptability or versatility
If Viperin homologs are utilized across different domains of life, then broad-spectrum antimicrobial activity is achieved, but the adaptability of the system to different physiological contexts becomes complex
Solution Approach 1:
The patent exploits parameter changes in Viperin homologs from different organisms to produce ddhNTP derivatives with varying properties. By selecting homologs with different substrate specificities (CTP, GTP, ATP), the system adapts to produce diverse derivatives tailored for specific therapeutic applications while maintaining the core mechanism.
Data Source
AI summary
The present invention provides for compositions and methods for deploying ddhNTPs as immunomodulatory therapeutics to modulate P2 receptors, as nucleotidase inhibitors, for applications like host-acting anti-infectives, oncolytics, anti-aging agents, or tissue regeneration agents.